# From brain to eye: Annexin A1 and A2 as a key mediator of retinal neuroinflammation in Parkinson’s and Alzheimer’s disease

**Authors:** Luiz Philipe de Souza Ferreira, Caio Vinicius Saito Regatieri

PMC · DOI: 10.1186/s40942-025-00786-y · International Journal of Retina and Vitreous · 2026-02-04

## TL;DR

Annexin A1 and A2 may help reduce retinal inflammation in Parkinson’s and Alzheimer’s diseases, offering potential new treatments.

## Contribution

Highlights annexin A1 and A2 as key regulators of retinal neuroinflammation in Parkinson’s and Alzheimer’s.

## Key findings

- Reduced AnxA1 activity may worsen inflammation in Parkinson’s retinal degeneration.
- AnxA1 signaling is crucial for clearing β-amyloid in Alzheimer’s retinal damage.
- AnxA1/AnxA2 pathways could serve as therapeutic targets for retinal degeneration in these diseases.

## Abstract

The retina, as an extension of the central nervous system, is highly susceptible to inflammatory and degenerative changes similar to those brain seen in Parkinson’s disease (PD) and Alzheimer’s disease (AD). Annexin A proteins, particularly annexin A1 (AnxA1) and annexin A2 (AnxA2), may play key roles in regulating neuroinflammation and maintaining retinal homeostasis. AnxA1 provides strong anti-inflammatory and pro-resolution actions, limiting cytokine release and promoting a reparative microglial phenotype. AnxA2, which often acts as an S100A10-AnxA2 complex, supports inflammatory resolution through tPA- and TLR4-dependent pathways and contributes to glial stability. In PD, retinal degeneration mirrors brain pathology, and reduced AnxA1 activity may impair the resolution of inflammation. In AD, decreased AnxA1 signalling compromises β-amyloid clearance and maintains chronic neuroinflammation. However, endogenous release of AnxA1 or therapy with AnxA1-derived peptides is capable of promoting efficient phagocytosis by microglia, clearing the neurotoxic environment in AD brains. Overall, it is possible that coordinated AnxA1/AnxA2 activity may mitigate retinal damage, improve the removal of toxic aggregates, and preserve vision, highlighting annexin pathways as promising therapeutic targets for retinal degeneration in PD and AD. This makes it an interesting target for study during retinal degeneration in PD and AD.

## Linked entities

- **Genes:** ANXA1 (annexin A1) [NCBI Gene 301], ANXA2 (annexin A2) [NCBI Gene 302]
- **Proteins:** ANXA1 (annexin A1), ANXA2 (annexin A2), S100A10 (S100 calcium binding protein A10), PLAT (plasminogen activator, tissue type), TLR4 (toll like receptor 4)
- **Diseases:** Parkinson’s disease (MONDO:0005180), Alzheimer’s disease (MONDO:0004975)

## Full-text entities

- **Genes:** ANXA1 (annexin A1) [NCBI Gene 301] {aka ANX1, LPC1}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, SNCA (synuclein alpha) [NCBI Gene 6622] {aka NACP, PARK1, PARK4, PD1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, MME (membrane metalloendopeptidase) [NCBI Gene 4311] {aka CALLA, CD10, CMT2T, NEP, SCA43, SFE}, FPR2 (formyl peptide receptor 2) [NCBI Gene 2358] {aka ALX, ALXR, FMLP-R-II, FMLPX, FPR2A, FPRH1}, PLAT (plasminogen activator, tissue type) [NCBI Gene 5327] {aka T-PA, TPA}, S100A10 (S100 calcium binding protein A10) [NCBI Gene 6281] {aka 42C, ANX2L, ANX2LG, CAL1L, CLP11, Ca[1]}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, PLG (plasminogen) [NCBI Gene 5340] {aka HAE4}, ANXA2 (annexin A2) [NCBI Gene 302] {aka ANX2, ANX2L4, CAL1H, HEL-S-270, LIP2, LPC2}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, S100A1 (S100 calcium binding protein A1) [NCBI Gene 6271] {aka S100, S100-alpha, S100A}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}
- **Diseases:** neurodegeneration (MESH:D019636), cerebral ischemic (MESH:D002547), neuroinflammation (MESH:D000090862), visual deficits (MESH:D014786), retinal and cerebral degeneration (MESH:D012162), brain inflammation (MESH:D004660), inflammatory damage (MESH:D018746), dopaminergic (MESH:D009422), neurotoxic (MESH:D020258), AD (MESH:D000544), amyloid (MESH:C000718787), inflammatory cytokines (MESH:D000080424), inflammation (MESH:D007249), PD (MESH:D010300), retinal damage (MESH:D012164), brain tissue injury (MESH:D001930)
- **Chemicals:** Ac2-26 (-), phospholipid (MESH:D010743)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12870342/full.md

---
Source: https://tomesphere.com/paper/PMC12870342